With early trial results showing up to 15% weight loss, the experimental GLP-1/GIP/glucagon drug UBT251 adds serious firepower to Novo Nordisk’s expanding metabolic pipeline.

In a move that underscores the white-hot race in obesity drug development, Novo Nordisk has inked an exclusive licensing agreement worth up to $2 billion with The United Laboratories (TUL) and its subsidiary United Biotechnology, acquiring global rights to UBT251, a first-in-class triple receptor agonist.

The deal includes a $200 million upfront payment and potential milestone payments of up to $1.8 billion, plus tiered royalties on future sales. TUL retains rights for Greater China (Mainland, Hong Kong, Macau, and Taiwan), while Novo Nordisk takes the reins globally for development and commercialization.

A Potent New Contender in the Obesity Drug Wars

UBT251 targets three key receptors:

• GLP-1 (glucagon-like peptide-1),

• GIP (glucose-dependent insulinotropic polypeptide), and

• Glucagon — all central players in regulating metabolism, appetite, and fat utilization.

In a recently completed Phase 1b trial in China involving 36 overweight or obese patients, the highest dose group saw an average weight loss of 15.1% over 12 weeks — a figure that rivals or exceeds current industry leaders. Importantly, the safety profile mirrored that of existing incretin therapies, with mostly mild-to-moderate gastrointestinal effects.

Novo Nordisk’s EVP of Development, Martin Holst Lange, highlighted the deal’s strategic importance:

“The addition of a candidate targeting glucagon, as well as GLP-1 and GIP, will add important optionality to our clinical pipeline as we build a differentiated portfolio for cardiometabolic disease.”

Expanding the Global Footprint

While Novo Nordisk brings scale and regulatory muscle, TUL sees the partnership as a launchpad for global innovation.

“This agreement is a pivotal milestone in our innovation-driven transformation,” said TUL Chairman Tsoi Hoi Shan.

UBT251 is currently undergoing Phase 2 trials in China, with ongoing studies in type 2 diabetes, obesity, MAFLD (metabolic dysfunction-associated fatty liver disease), and chronic kidney disease (CKD), including trials registered in the US.

A Strategic Leap in a Crowded Market

As competition in the metabolic disease space intensifies — particularly among titans like Novo Nordisk and Eli Lilly — triple agonists are emerging as the next evolutionary step beyond GLP-1 and GIP dual therapies like Wegovy or Mounjaro. These compounds may offer improved efficacy for both weight loss and metabolic control, including harder-to-treat conditions like fatty liver or renal complications.

This latest deal follows a series of Novo Nordisk’s strategic acquisitions and partnerships aimed at maintaining its leadership position in chronic disease therapeutics. By licensing UBT251, Novo not only accelerates its clinical pipeline but positions itself to capture growing global demand for advanced, multifaceted metabolic drugs.